The New England Journal of Medicine February 1, 2017 DOI:10.1056/NEJMc1616421
Autori: Franco Cosmi, Roberto Latini, Antonio Nicolucci
To the editor: In reporting the results of the Trial to Evaluate Cardiovascular and Other Longterm Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6), Marso et al. (Nov. 10 issue)1 describe a lower rate of cardiovascular events among patients with type 2 diabetes mellitus who received the glucagon-like peptide 1 (GLP-1) analogue semaglutide than among patients who received placebo. Their results are consistent with those in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial,2 which assessed the effects of another GLP-1 analogue, liraglutide.